Want to see AU:DXB full AI Analyst Report?
Top Page
Dimerix Limited
(Sydney:DXB)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.20
â–Ľ(-32.07% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (ongoing losses, negative/unstable cash flows, and negative equity in 2026). Technical indicators are somewhat constructive (positive MACD and price above key short/medium-term averages), but valuation is constrained by the lack of profitability and no dividend support.
Positive Factors
Low Leverage
Low leverage reduces debt-service pressure and the risk that borrowing costs constrain operating decisions. This gives Dimerix greater financial flexibility to direct available resources toward clinical development, partnering activity, and other priorities without a large fixed debt burden.
Negative Factors
Persistent Deep Losses
Persistent operating and net losses show that Dimerix has not yet converted its development platform into sustainable earnings. Continued losses can consume capital, limit reinvestment capacity, and increase dependence on future financing or successful partnering milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Low leverage reduces debt-service pressure and the risk that borrowing costs constrain operating decisions. This gives Dimerix greater financial flexibility to direct available resources toward clinical development, partnering activity, and other priorities without a large fixed debt burden.
Read all positive factors
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$120.08M
Dividend YieldN/A
Average Volume (3M)641.89K
Price to Earnings (P/E)―
Beta (1Y)2.65
Revenue Growth-22.13%
EPS Growth-108.82%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding600,396,800
10 Day Avg. Volume515,026
30 Day Avg. Volume641,888
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-8.34
Price to Sales (P/S)28.29
P/FCF Ratio-2.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$9.00M
Dimerix Limited Business Overview & Revenue Model
Company Description
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candid...
How the Company Makes Money
Dimerix primarily seeks to generate income through the development and out-licensing/commercial partnering of its drug candidates rather than through established product sales. The company’s potential revenue model is typically biopharma-based and...
Dimerix Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
30
Negative
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.35M | 1.25M | 583.48K | 36.79K | 6.46M |
| Gross Profit | 4.21M | 1.25M | 583.48K | 36.79K | 6.41M |
| EBITDA | -37.04M | -36.22M | -24.96M | -22.68M | -16.47M |
| Net Income | -29.81M | -13.25M | -17.07M | -13.80M | -10.49M |
Balance Sheet | |||||
| Total Assets | 58.59M | 91.18M | 32.08M | 17.76M | 16.50M |
| Cash, Cash Equivalents and Short-Term Investments | 16.15M | 68.28M | 22.14M | 7.99M | 9.63M |
| Total Debt | 232.09K | 97.48K | 149.68K | 5.96M | 73.10K |
| Total Liabilities | 73.35M | 77.80M | 13.89M | 11.79M | 2.07M |
| Stockholders Equity | -14.76M | 13.38M | 18.19M | 5.96M | 14.42M |
Cash Flow | |||||
| Free Cash Flow | -51.81M | 39.03M | -7.02M | -12.73M | -13.45M |
| Operating Cash Flow | -51.81M | 39.05M | -7.00M | -12.73M | -13.44M |
| Investing Cash Flow | -4.98K | -21.01K | -15.80K | -2.30K | -10.61K |
| Financing Cash Flow | 118.47K | 7.42M | 21.17M | 11.07M | 17.69M |
Dimerix Limited Technical Analysis
Negative
0.29
Price Trends
0.25
Negative
0.24
Negative
0.30
Negative
Market Momentum
-0.01
Positive
36.21
Neutral
13.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:DXB, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.25, and below the 200-day MA of 0.30, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 36.21 is Neutral, neither overbought nor oversold. The STOCH value of 13.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:DXB.
Dimerix Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$120.08M | -4.12 | 362.74% | ― | -22.13% | -108.82% | |
45 Neutral | AU$94.79M | -5.79 | 84.67% | ― | ― | 42.51% | |
44 Neutral | AU$158.84M | -8.54 | -103.42% | ― | ― | 5.88% | |
44 Neutral | AU$55.00M | -2.17 | -48.25% | ― | ― | -16.21% | |
44 Neutral | AU$32.43M | -0.41 | -98.86% | ― | ― | -27.73% | |
44 Neutral | AU$30.38M | -0.34 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
AU:DXB
Dimerix Limited
0.20
-0.30
-60.00%
AU:ACW
Actinogen Medical
0.04
<0.01
20.59%
AU:ATH
Alterity Therapeutics
0.24
-0.31
-56.36%
AU:IMM
Immutep Ltd
0.02
-0.26
-92.28%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.12
-91.85%
AU:RCE
Recce Pharmaceuticals Ltd.
0.31
-0.10
-23.46%
Dimerix Limited Corporate Events
Dimerix bolsters DMX-200 case with new FSGS inflammatory pathway data
Oct 22, 2026
Dimerix has highlighted new human data from the NEPTUNE cohort presented at Kidney Week 2026 that strengthens the biological rationale for its Phase 3 investigational therapy, DMX-200, in FSGS. The study of 261 patients showed that activation of t...
Dimerix targets rare kidney diseases as it steps up investor outreach in Australia and Hong Kong
Oct 11, 2026
Dimerix Limited, a clinical-stage biopharmaceutical company, is advancing a portfolio of kidney disease treatments led by DMX-200 for focal segmental glomerulosclerosis and DMX-652 for acute kidney injury. With orphan designations, long-dated pate...
Dimerix Marks Four-Year Milestone in DMX-200 FSGS Clinical Program
Oct 4, 2026
Dimerix has reported that the first patient in its DMX-200 program for focal segmental glomerulosclerosis has completed two years in the Open Label Extension study, following two years in the blinded ACTION3 Phase 3 trial. This marks four years of...
Dimerix Issues 9.35 Million Unquoted Options Under Employee Incentive Scheme
Sep 28, 2026
Dimerix Limited has notified the market of the issue of 9,350,000 unquoted options under its employee incentive scheme, with varying expiry dates and exercise prices. The new options, classified as DXBAX and issued on 21 September 2026, are subjec...
Dimerix Sets 2026 AGM as Kidney Disease Pipeline Advances
Sep 25, 2026
Dimerix Limited has scheduled its 2026 Annual General Meeting for 25 November in Melbourne, where shareholders will receive a strategic update from CEO and Managing Director Dr Nina Webster. The meeting and associated director nomination deadline ...
Dimerix to Showcase Kidney Disease Pipeline and Growth Strategy at ASX SMIDcaps Conference
Sep 22, 2026
Dimerix CEO Dr Nina Webster is presenting at the ASX SMIDcaps Conference in Sydney, outlining progress on the Phase 3 global trial of DMX-200 for FSGS, the Phase 2 program for DMX-652 in acute kidney injury, commercial partnerships and the company...
Dimerix Secures A$17m Non‑Dilutive Funding to Drive Kidney Disease Trials
Sep 22, 2026
Dimerix has completed an initial A$17 million drawdown from its previously announced A$34 million non‑dilutive funding facility, bolstering its balance sheet while only accessing half of the committed funds. The remaining A$17 million can be...
Dimerix Wins ASX Waiver to Secure Related-Party Funding in A$50m Facility
Sep 22, 2026
Dimerix has secured an ASX waiver of Listing Rule 10.1, allowing it to grant security over its assets to related-party lender Skiptan Entities without shareholder approval, in connection with a broader loan facility of up to A$50 million. The comp...
Dimerix to Showcase Kidney Disease Pipeline and Growth Strategy at E&P Healthcare Conference
Sep 15, 2026
Dimerix Limited will present its strategic and clinical progress at the EP Healthcare Conference in Sydney, underscoring its role as an emerging player in kidney disease therapeutics. CEO Dr Nina Webster is set to outline updates on the global Pha...
Dimerix Highlights Kidney Disease Focus and Development Risks in Investor Update
Sep 6, 2026
Dimerix Limited has released an investor presentation outlining its strategy to develop new therapies targeting kidney diseases with unmet clinical needs, signalling a continued emphasis on innovative drug development in the renal space. The updat...
S&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks
Sep 4, 2026
SP Dow Jones Indices has announced the results of its September 2026 quarterly rebalance of the SP/ASX indices, to take effect before trading opens on September 21. The SP/ASX 20 will remain unchanged, while the SP/ASX 50, 100, 200 and 300 indices...
Dimerix Seeks Trading Halt Ahead of Non-Dilutive Funding Update
Sep 1, 2026
Dimerix Limited has requested and received a trading halt on its ordinary shares from the Australian Securities Exchange, effective from the commencement of trading on Wednesday, 2 September 2026. The halt will remain in place until either normal ...
Dimerix Files 2026 Corporate Governance Disclosures with ASX
Aug 26, 2026
Dimerix Limited has lodged its Appendix 4G and confirmed the location of its corporate governance statement for the financial year ended 30 June 2026, in line with ASX Listing Rules. The statement, approved by the board, outlines how the company f...
Dimerix lifts revenue but annual loss more than doubles
Aug 26, 2026
Dimerix Limited is a publicly listed biopharmaceutical company focused on developing and commercialising therapies, with activities centred on research, clinical development and related operations. The group generates revenue from ordinary activit...
Dimerix Secures US$10m Everest Payment as DMX-200 Global Strategy Advances
Aug 20, 2026
Dimerix Limited, a clinical-stage biopharmaceutical company headquartered in Melbourne, is developing DMX-200 for the treatment of rare kidney diseases, most notably focal segmental glomerulosclerosis. The company is pursuing global market access ...
Dimerix Takes Control of U.S. IND for New Renal Asset DMX-652
Aug 16, 2026
Dimerix Limited, a Melbourne-based clinical-stage biopharmaceutical company, is building a portfolio of kidney disease treatments, led by its Phase 3 candidate DMX-200 for focal segmental glomerulosclerosis. The company is also progressing a Phase...
Dimerix highlights kidney disease pipeline and diversification strategy at Bioshares Summit
Aug 5, 2026
Dimerix Limited, a clinical-stage biopharmaceutical group, is building a specialised portfolio of kidney disease therapies centred on its lead candidate DMX-200 for focal segmental glomerulosclerosis. The company is also advancing DMX-652 for acut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.